Operating Income (Loss) in USD of Nurix Therapeutics, Inc. from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Nurix Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2019 to Q3 2025.
  • Nurix Therapeutics, Inc. Operating Income (Loss) for the quarter ending 31 Aug 2025 was -$91.4M, a 67.3% decline year-over-year.
  • Nurix Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 31 Aug 2025 was -$267M, a 38% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$213M, a 37.4% decline from 2023.
  • Nurix Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$155M, a 15.7% increase from 2022.
  • Nurix Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$184M, a 56% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$267M -$91.4M -$36.8M -67.3% 01 Jun 2025 31 Aug 2025 10-Q 09 Oct 2025
Q2 2025 -$230M -$48.3M +$218K +0.45% 01 Mar 2025 31 May 2025 10-Q 09 Jul 2025
Q1 2025 -$231M -$62.9M -$17.6M -39% 01 Dec 2024 28 Feb 2025 10-Q 08 Apr 2025
Q4 2024 -$213M -$64.7M -$19.3M -42.6% 01 Sep 2024 30 Nov 2024 10-K 28 Jan 2025
Q3 2024 -$194M -$54.6M -$14.6M -36.5% 01 Jun 2024 31 Aug 2024 10-Q 09 Oct 2025
Q2 2024 -$179M -$48.5M -$21.8M -81.4% 01 Mar 2024 31 May 2024 10-Q 09 Jul 2025
Q1 2024 -$157M -$45.2M -$2.27M -5.28% 01 Dec 2023 29 Feb 2024 10-Q 08 Apr 2025
Q4 2023 -$155M -$45.3M +$3.36M +6.89% 01 Sep 2023 30 Nov 2023 10-K 28 Jan 2025
Q3 2023 -$158M -$40M +$6.71M +14.4% 01 Jun 2023 31 Aug 2023 10-Q 11 Oct 2024
Q2 2023 -$165M -$26.8M +$19M +41.5% 01 Mar 2023 31 May 2023 10-Q 11 Jul 2024
Q1 2023 -$184M -$43M -$208K -0.49% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024
Q4 2022 -$184M -$48.7M -$10.7M -28.3% 01 Sep 2022 30 Nov 2022 10-K 28 Jan 2025
Q3 2022 -$173M -$46.7M -$17.7M -61.1% 01 Jun 2022 31 Aug 2022 10-Q 12 Oct 2023
Q2 2022 -$155M -$45.7M -$19.3M -73.1% 01 Mar 2022 31 May 2022 10-Q 13 Jul 2023
Q1 2022 -$136M -$42.7M -$18.2M -74.3% 01 Dec 2021 28 Feb 2022 10-Q 13 Apr 2023
Q4 2021 -$118M -$38M -$17.9M -89.7% 01 Sep 2021 30 Nov 2021 10-K 09 Feb 2023
Q3 2021 -$99.9M -$29M -$9.81M -51.1% 01 Jun 2021 31 Aug 2021 10-Q 06 Oct 2022
Q2 2021 -$90.1M -$26.4M -$13.2M -99.7% 01 Mar 2021 31 May 2021 10-Q 07 Jul 2022
Q1 2021 -$77M -$24.5M -$12M -95.3% 01 Dec 2020 28 Feb 2021 10-Q 08 Apr 2022
Q4 2020 -$65M -$20M 01 Sep 2020 30 Nov 2020 10-K 28 Jan 2022
Q3 2020 -$19.2M -$16.6M -635% 01 Jun 2020 31 Aug 2020 10-Q 14 Oct 2021
Q2 2020 -$13.2M 01 Mar 2020 31 May 2020 10-Q 13 Jul 2021
Q1 2020 -$12.6M 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021
Q3 2019 -$2.61M 01 Jun 2019 31 Aug 2019 10-Q 14 Oct 2020

Nurix Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$213M -$58M -37.4% 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2025
2023 -$155M +$28.8M +15.7% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2025
2022 -$184M -$66M -56% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025
2021 -$118M -$52.9M -81.4% 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023
2020 -$65M -$42.7M -192% 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022
2019 -$22.2M 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.